Expertise in
18
conditions

Julien Seneschal

Bordeaux, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
18
conditions
Bordeaux, FR 
OverviewLocationsClinical Research

Overview

Julien Seneschal practices in Bordeaux, France. Mr. Seneschal is highly rated in 18 conditions, according to our data. His top areas of expertise are Vitiligo, Hypomelanotic Disorder, Atopic Dermatitis, and Alopecia Areata.

His clinical research consists of co-authoring 224 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Bordeaux, France
Other Locations
Talence, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Efficacy and Tolerance of the Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults with Progressive Vitiligo: a Randomized Double-blind Prospective Study
Efficacy and Tolerance of the Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults with Progressive Vitiligo: a Randomized Double-blind Prospective Study
Enrollment Status: Recruiting
Publish Date: November 08, 2024
Intervention Type: Drug
Study Drug: Methotrexate
Study Phase: Phase 2
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: June 15, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis
Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Biological
Study Phase: Not Applicable
DUPECZEMAIN : Double Blind Placebo-controlled Randomized Multicenter Study Assessing the Efficacy and Safety of Dupilumab in Moderate to Severe Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
DUPECZEMAIN : Double Blind Placebo-controlled Randomized Multicenter Study Assessing the Efficacy and Safety of Dupilumab in Moderate to Severe Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
Enrollment Status: Completed
Publish Date: December 03, 2024
Intervention Type: Drug
Study Drug: Dupilumab
Study Phase: Phase 2
A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis
A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Baricitinib, Corticosteroid
Study Phase: Phase 3
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Biological
Study Phase: Not Applicable
Evaluation of Effect and Tolerance of the Association of Baricitinib (4 mg) and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized, Double-blind, Prospective, Non-comparative Phase II Study.
Evaluation of Effect and Tolerance of the Association of Baricitinib (4 mg) and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized, Double-blind, Prospective, Non-comparative Phase II Study.
Enrollment Status: Completed
Publish Date: June 13, 2023
Intervention Type: Drug
Study Drug: Baricitinib Oral Product
Study Phase: Phase 2
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
Enrollment Status: Completed
Publish Date: March 08, 2023
Intervention Type: Biological
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Biological
Vasculopathy, Inflammation and Systemic Sclerosis: The Role of Endothelial Cell Activation and OX40/OX40L in Modulation of T Lymphocyte Activation
Vasculopathy, Inflammation and Systemic Sclerosis: The Role of Endothelial Cell Activation and OX40/OX40L in Modulation of T Lymphocyte Activation
Enrollment Status: Completed
Publish Date: April 07, 2017
Intervention Type: Biological
Study Phase: Not Applicable
View 11 Less Clinical Trials

224 Total Publications

Progressive repigmentation of hypopigmented lesions in discoid lupus erythematosus with anifrolumab: A report of two cases.
Progressive repigmentation of hypopigmented lesions in discoid lupus erythematosus with anifrolumab: A report of two cases.
Journal: Lupus
Published: May 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Seneschal's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile